Addressing The Unique Challenges Of Cell And Gene Therapy Supply Chain Management

The cell and gene therapy (CGT) supply chain is marked by complexity and precision, as these life-saving therapies require stringent logistical controls. From personalized treatments that rely on a patient’s own cells to gene therapies that may be stored for future use, navigating the intricacies of cold chain logistics, packaging, and regulatory compliance is essential for safe and timely delivery. Each step—whether it’s transporting temperature-sensitive products or ensuring chain of custody—is critical to preserving product integrity and efficacy.

In this evolving landscape, CGT developers must work closely with supply chain experts to overcome these challenges, as well as adapt to regulatory guidelines that continue to evolve. During Cencora’s ThinkLive Cell and Gene Therapy Summit 2024, industry leaders discussed the unique hurdles of the CGT supply chain, sharing insights on streamlining logistics to improve patient access. As this field matures, technology-driven innovations like real-time tracking and digital twins are being harnessed to mitigate risks, while harmonization and standardization across global regulatory bodies remain crucial. The key is to build robust, scalable processes that ensure these therapies reach patients safely and efficiently.